|
مقاله
|
Abstract
|
|
|
|
Title:
|
Efficacy of intravitreal Bevacizumab for type 1 Retinopathy of Prematurity
|
|
Author(s):
|
Karkhaneh Reza*, Khodabande Alireza*, Riazi-Eafahani Mohammad*, Roohipoor Ramak, Ghassemi Fariba*, Imani Marjan*, Dastjani Farahani Afsar*
|
|
Presentation Type:
|
Oral
|
|
Subject:
|
Posterior Segment and Uveitis
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Ali reza Khoda Bandeh
|
|
Affiliation :(optional)
|
Farabi Eye Research center
|
|
E mail:
|
alireza_khodabande@yahoo.com
|
|
Phone:
|
|
|
Mobile:
|
09132137426
|
|
|
|
|
Purpose:
|
to assess the effect of intravitreal Bevacizumab for type 1 retinopathy of prematurity
|
|
Methods:
|
Study Population: Infants with type 1 ROP.
Intervention Procedure: All eligible zone-I infants received intravitreal Bevacizumab injections. Zone-II eligible infants were randomized to receive either conventional indirect laser therapy or intravitreal Bevacizumab injections.
Main Outcome Measure: The primary outcome was defined as ROP persistence or recurrence by 90 weeks’ postmenstrual age
|
|
Results:
|
26 eyes with zone-I and 176 eyes with zone-II ROP were enrolled. All the zone-I infants received intravitreal Bevacizumab. 88 eyes in the zone-II group were randomly assigned to receive intravitreal Bevacizumab and 88 eyes to undergo conventional laser therapy. Of the 26 eyes in the zone-I group completing the follow-up period, ROP regressed in 20 eyes without recurrence. Six eyes (5 infants) received a second injection because of disease recurrence.
In the zone-II infants, stage-3 ROP recurred in 9 eyes (10.5%) in the Avastin group and one eye (1.4%) in the laser group (P value=0.018)
|
|
Conclusion:
|
Recurrence of neovascularization with Avastin monotherapy seems to be higher than that with conventional laser therapy among infants with zone-II ROP. Reinjection of Bevacizumab causes regression in most recurrent cases.
|
|
Attachment:
|
|
|